DynoSense this week announced that it received FDA clearance for its Vital Signs Measuring System.
The wireless system can capture electrocardiogram, respiration rate, oral body temperature, functional oxygen saturation of arterial hemoglobin, optical photoplethysmogram for pulse rate and heart rate. The device communicates with any smartphone using its DynoLife application that can send raw data from the system to the cloud for computation. The data is analyzed in the cloud by an intelligent analytic engine to help clinicians interpret the metric. It can also alert then to changes in blood pressure, perfusion index, different types of cardiac ailments and other capabilities through the intelligent analytic engine.
“I am very proud of our technological accomplishments and proven capabilities to date,” CEO Saeed Azimi said in a press release. ‘We are on the path to take advantage of the shift to advanced AI-based monitoring systems and digital therapeutic methods to improve health and wellness. As a person with my own chronic health condition, I have come to understand the power of receiving informed preventative and self-empowering alerts that are coupled with my clinical care specialists.”
DynoSense plans to have the technology fully commercially ready and available by the first half of 2020 and has so far collected over 100,000 data sets from various trials and is extending datasets as it collaborates with partners.
“DynoSense has built incredibly strong advanced technologies and capabilities for addressing the large nascent market in the Asia region,” Ryan Wong, CEO of Evvo Labs, said. “We are planning for exciting business opportunities and go-to-market strategies with them.”
“A new era of cloud-based health monitoring and analysis systems is upon us,” professor of medicine and Silicon Valley biotech consultant Lee Winters said. “This will radically change the practice of medicine and usher in new ways of caring for patients especially those in outlying and rural locations.”